Geneos Wealth Management’s Filana Therapeutics FLNA Stock Holding History

Geneos Wealth Management’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-75	Closed	-$2.21K	–	2953
2024 Q3	$2.21K	Hold	75	–	–	﹤0.01%	2279
2024 Q2	$926	Hold	75	–	–	﹤0.01%	1990
2024 Q1	$1.52K	Hold	75	–	–	﹤0.01%	1941
2023 Q4	$1.69K	Hold	75	–	–	﹤0.01%	1945
2023 Q3	$1.25K	Buy	+75	New	+$1.49K	﹤0.01%	1996
2022 Q3	–	Sell	-339	Closed	-$8K	–	2489
2022 Q2	$8K	Hold	339	–	–	﹤0.01%	2047
2022 Q1	$12K	Sell	339 -100	-23%	-$4.24K	﹤0.01%	2020
2021 Q4	$19K	Hold	439	–	–	﹤0.01%	1913
2021 Q3	$26K	Buy	439 +195	+80%	+$16.3K	﹤0.01%	1791
2021 Q2	$21K	Hold	244	–	–	﹤0.01%	1902
2021 Q1	$11K	Hold	244	–	–	﹤0.01%	2354
2020 Q4	$11K	Buy	244 +100	+69%	+$893	﹤0.01%	2192
2020 Q3	$1K	Buy	+144	New	+$649	﹤0.01%	2562

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Geneos Wealth Management's FLNA Position: Q4 2024 in Review

Geneos Wealth Management sold out of Filana Therapeutics (FLNA) in Q4 2024, closing a stake of 75 shares — an estimated $2.21K sold.

Geneos Wealth Management first reported a position in FLNA in Q3 2020 and held it in 13 quarters. The position peaked at $26K in Q3 2021. 137 funds tracked by Wall St. Rank hold FLNA as of Q4 2024.

Geneos Wealth Management reported no remaining Filana Therapeutics position as of Q4 2024 after selling out during the quarter.
Geneos Wealth Management sold 75 Filana Therapeutics shares in Q4 2024, an estimated $2.21K.
Geneos Wealth Management first reported a position in Filana Therapeutics in Q3 2020 and held it in 13 quarters.
Geneos Wealth Management's Filana Therapeutics position peaked at $26K in Q3 2021.
137 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2024.

Based on Geneos Wealth Management's 13F filing for Q4 2024, filed 21 Jan 2025.